Navigation Links
Boston Scientific Launches Educational Initiative to Address Disparities in Cardiovascular Care
Date:2/4/2008

'Close the Gap' brings together advocates from cardiologists to coaches

NATICK, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the public debut of an educational initiative called "Close the Gap," which is aimed at addressing disparities in cardiovascular care for the underserved patient populations of women, black Americans and Latino Americans. The Company said it is collaborating on the Close the Gap initiative with a number of organizations, including WomenHeart, Black Coaches and Administrators, the Athlete's Heartbeat and the National Coalition of Pastors' Spouses. Several National Collegiate Athletic Association (NCAA) member schools are also supporting Close the Gap efforts. The campaign is being led by a steering committee of leading physicians from across the country and will have a strong focus on community education.

"Heart disease causes more deaths in Americans of both sexes and all racial and ethnic groups than any other disease," said Close the Gap steering committee member Charles Noble, M.D., a Columbus, Ohio-based electrophysiologist and incoming Vice President of the Association of Black Cardiologists. "Many different medical conditions or lifestyle habits can affect one's chance of developing heart disease. Close the Gap seeks to help Americans understand risk factors and know what actions can be taken to lower their risk of developing heart disease."

Close the Gap will work to increase awareness of cardiovascular risk factors through community programs involving faith-based organizations, collegiate and professional athletic teams, and patient advocacy groups.

A key focus of the campaign will be to raise awareness of sudden cardiac arrest as
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Mediterranean diet associated with reduced risk of depression 10311 1Mediterranean diet associated with reduced risk of depression 10311 2Common herbicides and fibrates block nutrient sensing receptor found in gut and pancreas 10307 1Common herbicides and fibrates block nutrient sensing receptor found in gut and pancreas 10307 2Miscarriage Treatment Wont Harm Future Fertility 3A Study 59205 1Miscarriage Treatment Wont Harm Future Fertility 3A Study 59205 2